Explore more publications!

Press Releases

REPRONOVO APPOINTS MARK ALTMEYER AS  CHAIRMAN OF THE BOARD
Aalberts N.V.: Aalberts completes divestment Broen in Denmark
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Feed Additives Market Set to Reach $67.90 Billion by 2031 Driven by Rising Demand for Animal Nutrition
Denmark Targets Ukrainian Refugees with Policy Changes

Denmark Targets Ukrainian Refugees with Policy Changes

Nordic MSPs Can Now Access Heimdal's Unified Security and Compliance Platform Through Elovade
Sweden, Denmark Are Open to Hosting NATO Nuclear Arms

Sweden, Denmark Are Open to Hosting NATO Nuclear Arms

Denmark's King Frederik X Makes Greenland Visit

Denmark's King Frederik X Makes Greenland Visit

Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Denmark’s King Visits Greenland to Signal Support Amid Arctic Spotlight

Denmark’s King Visits Greenland to Signal Support Amid Arctic Spotlight

Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
AsiaCorp and Whiteflock Brand Management Form Strategic Partnership to Expand Global Brands in India
Notice to convene Evaxion’s Annual General Meeting
Nordic MSPs Can Now Access Heimdal's Unified Security and Compliance Platform Through Elovade
VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
National Center on Education and the Economy (NCEE) Names Global High Performing Countries in Education
NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
Priavoid Presents Preclinical Proof-of-Concept for PRI-101 Demonstrating α-synuclein Aggregate Disassembly  at AD/PD™ 2026

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions